Rare disease therapeutics Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
13:48
Jan 13
Jan 13
Rare disease market has global unmet need
Rare diseases are a major healthcare opportunity despite small individual patient populations: about 10,000 rare diseases affect roughly 10% of the population, diagnosis is difficult, and products can be globalized. Spinraza has about 15,000 patients worldwide, 9,000 outside the U.S. Low operating costs and government willingness to pay for unmet need can support programs like Friedreich's ataxia at $1B-$1.5B, and rare-disease capabilities can transfer to complex non-rare diseases such as lupus.
HIGH
About Rare disease therapeutics Investor Commentary
Across the available history and selected sources, Buzzberg tracks Rare disease therapeutics across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Chris Viehbacher.